{"id":"W4309095504","doi":"10.1111/jdv.18727","title":"Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase <scp>IIa</scp> study","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Eczema Area and Severity Index; Medicine; Atopic dermatitis; Placebo; Clinical endpoint; Internal medicine; Dermatology Life Quality Index; Randomized controlled trial; Adverse effect; Gastroenterology; Interleukin; Minimal clinically important difference; Immunology; Cytokine; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003808803,0.001210899,0.002454578,0.0002809,0.000285793,0.0007614506,0.0005652571,0.001362244,0.002341717],"category_scores_gemma":[0.002054246,0.0004722218,0.00305206,0.0003534592,0.0006510972,0.0006553371,0.0002632611,0.001395427,0.0003893174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004488108,"about_ca_system_score_gemma":0.0008424757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003724078,"about_ca_topic_score_gemma":0.0008059212,"domain_scores_codex":[0.9989733,0.0005890055,0.00009803521,0.000138141,0.0001045823,0.0000970862],"domain_scores_gemma":[0.9986362,0.0004298516,0.0003723278,0.0001124507,0.000124166,0.0003249592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9335796,0.007423834,0.004162009,0.001455294,0.003703231,0.0001113374,0.0001063253,0.0006010828,0.01371267,0.00006895004,0.0009129019,0.03416267],"study_design_scores_gemma":[0.8462186,0.1346842,0.01458699,0.00007383637,0.002157046,0.0001574539,0.00002520368,0.0003430376,0.0008415238,0.00007928877,0.0008097063,0.0000230869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862366,0.009888527,0.0005948759,0.0003702937,0.0001889757,0.001250265,0.0005544068,0.000053961,0.0008621838],"genre_scores_gemma":[0.9920945,0.003457598,0.001054072,0.0007399925,0.0002435902,0.0008639655,0.0008403995,0.00001144603,0.000694345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003808803,"threshold_uncertainty_score":0.02014309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01578358690722524,"score_gpt":0.2898311746365674,"score_spread":0.2740475877293422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}